$VKTX has shown a significant increase, rising by 6% and maintaining a trading range between $60 and $70, which is considered favorable for swing trades. Investors are employing strategies such as buying call options during dips and selling during upticks to capitalize on profits without altering their long positions in common shares. The company recently achieved a court ruling in favor of its drug VK2809, while its other drug VK2735, aimed at obesity, is reported to have no patent issues. This positive news has contributed to the current bullish sentiment surrounding the stock, with some investors actively trading options for short-term gains.